These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 10049277)

  • 21. The role of gram-negative bacteria in healthcare-associated pneumonia.
    Restrepo MI; Anzueto A
    Semin Respir Crit Care Med; 2009 Feb; 30(1):61-6. PubMed ID: 19199188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study.
    Tod M; Minozzi C; Beaucaire G; Ponsonnet D; Cougnard J; Petitjean O
    J Antimicrob Chemother; 1999 Jul; 44(1):99-108. PubMed ID: 10459816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.
    Sumi CD; Heffernan AJ; Lipman J; Roberts JA; Sime FB
    Clin Pharmacokinet; 2019 Nov; 58(11):1407-1443. PubMed ID: 31325141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
    Scaglione F; Esposito S; Leone S; Lucini V; Pannacci M; Ma L; Drusano GL
    Eur Respir J; 2009 Aug; 34(2):394-400. PubMed ID: 19213786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The vicissitude of pathogenic bacteria isolated from critically ill patients in an intensive care unit during a period of using antibiotics].
    Wei HJ; Liu LL; Xiaoli LY; Wang YP; Huang D; Pian HY; Zhu YC
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Jan; 21(1):36-9. PubMed ID: 19141190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
    Beaucaire G
    J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
    Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ
    Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia.
    Gruson D; Hilbert G; Vargas F; Valentino R; Bui N; Pereyre S; Bebear C; Bebear CM; Gbikpi-Benissan G
    Crit Care Med; 2003 Jul; 31(7):1908-14. PubMed ID: 12847382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging drugs for nosocomial pneumonia.
    Liapikou A; Torres A
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):331-41. PubMed ID: 27347712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices.
    Heintz BH; Thompson GR; Dager WE
    Ann Pharmacother; 2011 Nov; 45(11):1338-45. PubMed ID: 22010003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug treatment of pneumonia in the hospital. What are the choices?
    Aoun M; Klastersky J
    Drugs; 1991 Dec; 42(6):962-73. PubMed ID: 1724642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
    Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
    J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
    Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of severe infections: should one always administer an aminoglycoside?].
    Cometta A; Baumgartner JD
    Schweiz Med Wochenschr Suppl; 1996; 76():28S-33S. PubMed ID: 8677416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of organism species on microbial eradication and development of resistance in severe gram-negative pneumonia.
    Kiem S; Schentag JJ
    J Chemother; 2010 Apr; 22(2):103-9. PubMed ID: 20435569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill.
    Pugh RJ; Cooke RP; Dempsey G
    J Hosp Infect; 2010 Apr; 74(4):337-43. PubMed ID: 20202717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Michalopoulos A; Kasiakou SK; Mastora Z; Rellos K; Kapaskelis AM; Falagas ME
    Crit Care; 2005 Feb; 9(1):R53-9. PubMed ID: 15693967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
    Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.